Matches in SemOpenAlex for { <https://semopenalex.org/work/W4249498002> ?p ?o ?g. }
- W4249498002 abstract "Background Myasthenia gravis is an autoimmune disease in which autoantibodies interfere with neuromuscular transmission. As with other autoimmune diseases, people with myasthenia gravis would be expected to benefit from intravenous immunoglobulin (IVIg). Objectives The objective of this review was to examine the efficacy of intravenous immunoglobulin for treating exacerbations of myasthenia gravis or for chronic myasthenia gravis. Search methods We searched the Cochrane Neuromuscular Disease GroupTrials Register (April 2007) and MEDLINE (January 1966 to May 2007) using 'myasthenia gravis' and 'intravenous immunoglobulin' as the search terms. Selection criteria We included all randomised or quasi‐randomised trials in which intravenous immunoglobulin was compared with no treatment, placebo or plasma exchange, in people with myasthenia gravis. Data collection and analysis One review author extracted the data and two others checked these data and the source from which they were derived. For methodological reasons, no formal meta‐analysis was performed. Main results We identified six randomised controlled trials, all of which investigated short‐term benefit. A trial of IVIg compared with placebo including 51 patients provided evidence for the effectiveness of IVIg in myasthenia gravis worsening. A study of 87 participants with exacerbation found no statistically significant difference between immunoglobulin and plasma exchange after two weeks. A study of 12 participants with moderate or severe myasthenia gravis treated in a crossover design trial found no statistically significant difference in the efficacy of immunoglobulin and plasma exchange after four weeks. A study with 15 participants with mild or moderate myasthenia gravis found no statistically significant difference in efficacy of IVIg and placebo after six weeks. A study included 33 participants with moderate exacerbations of myasthenia gravis and showed no statistically significant difference in the efficacy of IVIg and methylprednisolone. The last trial including 173 people with myasthenia gravis exacerbations, showed no superiority of IVIg 1 g/kg on two consecutive days over IVIg 1 g/kg on a single day. Authors' conclusions In exacerbation of myasthenia gravis, one randomised controlled trial of IVIg versus placebo demonstrated the efficacy of IVIg and another did not show a significant difference between IVIg and plasma exchange. Another showed no significant difference in efficacy between 1 g/kg and 2 g/kg of IVIg. A further, but underpowered, trial showed no significant difference between IVIg and oral methylprednisolone. In chronic myasthenia gravis, there is insufficient evidence from randomised trials to determine whether IVIg is efficacious. More research is needed to determine whether IVIg reduces the need for corticosteroids as suggested by two case series." @default.
- W4249498002 created "2022-05-12" @default.
- W4249498002 creator A5027976216 @default.
- W4249498002 creator A5029354822 @default.
- W4249498002 creator A5052673276 @default.
- W4249498002 date "2008-01-23" @default.
- W4249498002 modified "2023-10-18" @default.
- W4249498002 title "Intravenous immunoglobulin for myasthenia gravis" @default.
- W4249498002 cites W1647526924 @default.
- W4249498002 cites W1964773960 @default.
- W4249498002 cites W1971022805 @default.
- W4249498002 cites W1975133991 @default.
- W4249498002 cites W1978574602 @default.
- W4249498002 cites W1979105454 @default.
- W4249498002 cites W1979470935 @default.
- W4249498002 cites W1979820418 @default.
- W4249498002 cites W1993520265 @default.
- W4249498002 cites W1993694158 @default.
- W4249498002 cites W1994505790 @default.
- W4249498002 cites W2001447887 @default.
- W4249498002 cites W2004462852 @default.
- W4249498002 cites W2021441723 @default.
- W4249498002 cites W2027716010 @default.
- W4249498002 cites W2038125085 @default.
- W4249498002 cites W2048575240 @default.
- W4249498002 cites W2049792271 @default.
- W4249498002 cites W2054196862 @default.
- W4249498002 cites W2054456664 @default.
- W4249498002 cites W2064436710 @default.
- W4249498002 cites W2068001029 @default.
- W4249498002 cites W2071666533 @default.
- W4249498002 cites W2076655703 @default.
- W4249498002 cites W2078425070 @default.
- W4249498002 cites W2088678446 @default.
- W4249498002 cites W2092730158 @default.
- W4249498002 cites W2107024251 @default.
- W4249498002 cites W2109351747 @default.
- W4249498002 cites W2130448030 @default.
- W4249498002 cites W2157199750 @default.
- W4249498002 cites W2157547060 @default.
- W4249498002 cites W2163543567 @default.
- W4249498002 cites W2315610003 @default.
- W4249498002 cites W2336806052 @default.
- W4249498002 cites W2593534903 @default.
- W4249498002 cites W3021602716 @default.
- W4249498002 cites W380350233 @default.
- W4249498002 cites W4231335520 @default.
- W4249498002 cites W4231768803 @default.
- W4249498002 cites W4255171672 @default.
- W4249498002 doi "https://doi.org/10.1002/14651858.cd002277.pub3" @default.
- W4249498002 hasPublicationYear "2008" @default.
- W4249498002 type Work @default.
- W4249498002 citedByCount "54" @default.
- W4249498002 countsByYear W42494980022012 @default.
- W4249498002 countsByYear W42494980022013 @default.
- W4249498002 countsByYear W42494980022014 @default.
- W4249498002 countsByYear W42494980022015 @default.
- W4249498002 countsByYear W42494980022016 @default.
- W4249498002 countsByYear W42494980022018 @default.
- W4249498002 countsByYear W42494980022019 @default.
- W4249498002 countsByYear W42494980022020 @default.
- W4249498002 countsByYear W42494980022021 @default.
- W4249498002 countsByYear W42494980022022 @default.
- W4249498002 crossrefType "reference-entry" @default.
- W4249498002 hasAuthorship W4249498002A5027976216 @default.
- W4249498002 hasAuthorship W4249498002A5029354822 @default.
- W4249498002 hasAuthorship W4249498002A5052673276 @default.
- W4249498002 hasConcept C126322002 @default.
- W4249498002 hasConcept C142724271 @default.
- W4249498002 hasConcept C159654299 @default.
- W4249498002 hasConcept C203014093 @default.
- W4249498002 hasConcept C204787440 @default.
- W4249498002 hasConcept C27081682 @default.
- W4249498002 hasConcept C2776356578 @default.
- W4249498002 hasConcept C2777014857 @default.
- W4249498002 hasConcept C2778105408 @default.
- W4249498002 hasConcept C2779075594 @default.
- W4249498002 hasConcept C2779134260 @default.
- W4249498002 hasConcept C535046627 @default.
- W4249498002 hasConcept C71924100 @default.
- W4249498002 hasConceptScore W4249498002C126322002 @default.
- W4249498002 hasConceptScore W4249498002C142724271 @default.
- W4249498002 hasConceptScore W4249498002C159654299 @default.
- W4249498002 hasConceptScore W4249498002C203014093 @default.
- W4249498002 hasConceptScore W4249498002C204787440 @default.
- W4249498002 hasConceptScore W4249498002C27081682 @default.
- W4249498002 hasConceptScore W4249498002C2776356578 @default.
- W4249498002 hasConceptScore W4249498002C2777014857 @default.
- W4249498002 hasConceptScore W4249498002C2778105408 @default.
- W4249498002 hasConceptScore W4249498002C2779075594 @default.
- W4249498002 hasConceptScore W4249498002C2779134260 @default.
- W4249498002 hasConceptScore W4249498002C535046627 @default.
- W4249498002 hasConceptScore W4249498002C71924100 @default.
- W4249498002 hasLocation W42494980021 @default.
- W4249498002 hasOpenAccess W4249498002 @default.
- W4249498002 hasPrimaryLocation W42494980021 @default.
- W4249498002 hasRelatedWork W2019181620 @default.
- W4249498002 hasRelatedWork W2026980443 @default.
- W4249498002 hasRelatedWork W2050839888 @default.
- W4249498002 hasRelatedWork W2057968126 @default.